Table 4.
Relationships between rs966423 variants and histopathological and clinical factors.
| Feature | TT (n = 414) | CC/CT (n = 1052) | Total (n = 1466) | p-Value |
|---|---|---|---|---|
| Gender, n (%) | ||||
| Female | 366 (88.4%) | 903 (85.8%) | 1269 (86.6%) | |
| Male | 48 (11.6%) | 149 (14.2%) | 197 (13.4%) | 0.1941 |
| Median age at diagnosis, years (Q1–Q3; range) | 51.0 (40.0–60.0; 15.0–85.0) | 51.0 (39.0–59.0; 15–85) | 51.0 (39.0–59.8; 15–85) | 0.836 |
| Age at diagnosis, ≥ 55 years, n (%) | 162 (39.1%) | 398 (37.8%) | 560 (38.2%) | 0.6453 |
| Median tumor size, mm (Q1–Q3; range) | 9.0 (6.0–17.8; 0.0–80.0 ) | 9.0 (5.0–15.0; 0.0–130) | 9.0 (5.0–16.0; 0.0–130 ) | 0.126 |
| TC main type, n (%) | ||||
| FTC | 14 (3.4%) | 20 (1.9%) | 34 (2.3%) | |
| Oxyphilic | 2 (0.5%) | 2 (0.2%) | 4 (0.3%) | |
| PDTC | 12 (2.9%) | 30 (2.9%) | 42 (2.9%) | |
| PTC | 386 (93.2%) | 1000 (95.1%) | 1386 (94.5%) | 0.2411 |
| Multifocality, n (%) | ||||
| No | 315 (76.1%) | 773 (73.5%) | 1088 (74.2%) | |
| Yes | 99 (23.9%) | 279 (26.5%) | 378 (25.8%) | 0.3042 |
| Extrathyroidal extension, n (%) | ||||
| No | 333 (80.4%) | 843 (80.1%) | 1176 (80.2%) | |
| Minor | 73 (17.6%) | 194 (18.4%) | 267 (18.2%) | |
| Gross | 8 (1.9%) | 15 (1.4%) | 23 (1.6%) | 0.7424 |
| Angioinvasion, n (%) | ||||
| No | 381 (92.0%) | 986 (93.7%) | 1367 (93.2%) | |
| Yes | 33 (8.0%) | 66 (6.3%) | 99 (6.8%) | 0.2437 |
| Tumor stage, n (%) | ||||
| pT0 | 1 (0.2%) | 1 (0.1%) | 2 (0.1%) | |
| pT1a | 227 (54.8%) | 632 (60.1%) | 859 (58.6%) | |
| pT1b | 102 (24.6%) | 231 (22.0%) | 333 (22.7%) | |
| pT2 | 50 (12.1%) | 118 (11.2%) | 168 (11.5%) | |
| pT3a | 23 (5.6%) | 54 (5.1%) | 77 (5.3%) | |
| pT3b | 5 (1.2%) | 6 (0.6%) | 11 (0.8%) | |
| pT4a | 5 (1.2%) | 7 (0.7%) | 12 (0.8%) | |
| pT4b | 1 (0.2%) | 3 (0.3%) | 4 (0.3%) | 0.4434 |
| Node stage, n (%) | ||||
| N0a | 208 (50.2%) | 562 (53.4%) | 770 (52.5%) | |
| N0b | 134 (32.4%) | 344 (32.7%) | 478 (32.6%) | |
| N1a | 48 (11.6%) | 102 (9.7%) | 150 (10.2%) | |
| N1b | 24 (5.8%) | 44 (4.2%) | 68 (4.6%) | 0.3479 |
| Distant metastasis, n (%) | ||||
| M0 | 402 (97.1%) | 1030 (97.9%) | 1432 (97.7%) | |
| M1 | 12 (2.9%) | 22 (2.1%) | 34 (2.3%) | 0.3552 |
| 8th edition of TNM staging, n (%) | ||||
| I | 375 (90.6%) | 967 (91.9%) | 1342 (91.5%) | |
| II | 31 (7.5%) | 67 (6.4%) | 98 (6.7%) | |
| III | 2 (0.5%) | 2 (0.2%) | 4 (0.3%) | |
| Iva | 1 (0.2%) | 2 (0.2%) | 3 (0.2%) | |
| Ivb | 5 (1.2%) | 14 (1.3%) | 19 (1.3%) | 0.7103 |
| ATA initial risk, n (%) | ||||
| Low | 264 (63.8%) | 695 (66.1%) | 959 (65.4%) | |
| Intermediate | 118 (28.5%) | 298 (28.3%) | 416 (28.4%) | |
| High | 32 (7.7%) | 59 (5.6%) | 91 (6.2%) | 0.3018 |
| Response to initial therapy, n (%) | ||||
| Excellent | 319 (83.5%) | 797 (82.8%) | 1116 (83.1%) | |
| Indeterminate | 45 (11.8%) | 115 (12%) | 160 (11.9%) | |
| Biochemical incomplete | 9 (2.4%) | 23 (2.4%) | 32 (2.4%) | |
| Structural incomplete | 8 (2.1%) | 27 (2.8%) | 35 (2.6%) | 0.9528 |
| Final follow-up, n (%) | ||||
| NED | 346 (91.1%) | 880 (91.5%) | 1226 (91.3%) | |
| Indeterminate | 25 (6.6%) | 44 (4.6%) | 69 (5.1%) | |
| Biochemical incomplete | 4 (1.1%) | 10 (1.0%) | 14 (1.1%) | |
| Structural incomplete | 5 (1.2%) | 28 (2.9%) | 33 (2.5%) | 0.280 |
| Follow-up: recurrence after NED, n (%) | ||||
| No | 317 (99.4%) | 789 (99%) | 1106 (99.1%) | |
| Yes | 2 (0.6%) | 8 (1.0%) | 10 (0.9%) | 0.7852 |
| Death, n (%) | ||||
| No | 408 (98.6%) | 1037 (98.6%) | 1445 (98.6%) | |
| TC-unrelated | 3 (0.7%) | 3 (0.3%) | 6 (0.4%) | |
| TC-related | 3 (0.7%) | 12 (1.1%) | 15 (1.0%) | 0.9729 |
| Median follow-up time, years (range) | 5.0 (0.0–27.0) | 5.0 (0.0–40.0) | 5.0 (0.0–40.0) | 0.360 |
TC, thyroid cancer; FTC, follicular thyroid carcinoma; PDTC, poorly differentiated thyroid carcinoma; PTC, papillary thyroid carcinoma; ATA, American Thyroid Association; TNM, tumor node metastasis; NED, no evidence of disease.